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the overall cost (€884) was not ﬁnanced by Social Security, and
the majority of this cost corresponded to caregiver associated
cost (salaries and productivity lost). The caregiver economical
burden represents 68% of the overall cost-of-illness. CONCLU-
SIONS: Monthly overall mean cost of AD was high in Spain
(€1078), More than 80% of the cost-of-illness is funded by the
own patient family, adding an economical burden to the suffer-
ing of these families.
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OBJECTIVES: International studies have reported that patients
with ADHD incur higher health care costs than persons without
this condition, but little is known about the direct medical costs
associated with ADHD in Germany. The present study aims at
ﬁlling this void. METHODS: Health care resource utilization
data for patients with a diagnosis of ADHD (F90.0 and/or F90.1)
were extracted from the Nordbaden claims database (for year
2003), covering the complete regional population insured by
Statutory Health Insurance SHI (2.238 million lives in 2003),
and were combined with SHI prescription data. Complete
datasets were available for 3,831 outpatients with ADHD and
for a randomly selected control group matched 1:1 by age and
gender. For costing, resource use was valued applying SHI acqui-
sition costs. RESULTS: The annual average expenditure (direct
medical costs borne by SHI) per patient was €650 versus €251 for
matched controls, with physician charges accounting for 68%
(€444 versus €170 for controls). All categories of costs were
higher for patients with ADHD by a factor of 2 to 5 versus
controls, an observation that was consistent across age and
gender deﬁned subgroups. Average expenditures per patient with
ADHD increased with age (age group <7 years, €520; 7–12 years,
€622; 13–19 years, €661; >20 years, €1147), primarily reﬂecting
higher medication costs. In contrast, average costs per control
person showed little change across age groups (at €269, €245,
€250, and €272, respectively). Among children and adolescents,
there were no substantial spending differences by gender. CON-
CLUSIONS: These data are likely underestimates of the total
expenditures attributable to ADHD since they do neither include
costs of inpatient treatment nor cost of ergotherapeutic interven-
tions, which will have to be addressed in future studies. They
provide, for the ﬁrst time, robust information from Germany on
the signiﬁcant ﬁnancial burden for the SHI attributable to
ADHD.
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The type of antipsychotic determines the efﬁcacy and the toler-
ability for the patient. Long acting depot formulations were
designed to increase patient adherence to treatment. The second
generation atypical antipsychotics and long-acting injectable ris-
peridone (LAIR) in particular are more costly than conventional
antipsychotics, but may improve outcome of treatment; hence,
reducing costs associated with schizophrenia. OBJECTIVES:
Firstly, to provide estimates of the economic impact of schizo-
phrenia in Germany and to illustrate the cost-drivers in the
disease. Secondly, to present ﬁndings from a literature search of
published cost-effectiveness analyses of second generation schizo-
phrenia treatment, with focus on depot treatment. METHODS:
Based on data from the German Federal Bureau of Statistics,
the costs of schizophrenia were estimated from a top-down
approach. Additionally, costs were illustrated from a bottom-up
prevalence approach, based on data from published literature. A
literature search, using PubMed, was conducted to ﬁnd cost-
effectiveness data. RESULTS: Using a top-down approach, total
cost of schizophrenia in Germany was estimated to €7298
million in 2004. Direct and indirect costs were estimated to
€2715 and €4583 million respectively. Hospital stays represented
the largest share of the direct costs while invalidity was the main
reason for indirect costs. From the bottom-up approach, the total
cost of schizophrenia was estimated to between €4,920 million
and €10,420 million per year. The review of available economic
models shows that LAIR has a substantial cost advantage and
has been demonstrated to be cost- effective compared to alterna-
tive treatments. CONCLUSIONS: Schizophrenia is associated
with high health care and societal costs. LAIR has the potential
to improving the outcome of treatment, e.g. compliance; hence,
lower the costs associated with schizophrenia. Longer trials in a
naturalistic setting and studies regarding patient satisfaction of
LAIR are however requested.
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OBJECTIVES: While the substantial economic burden of depres-
sion is well documented, less is known about the cost of depres-
sion by clinical severity levels. This study’s objective is to
document the health care resource utilization and costs by sever-
ity for patients with major depressive disorder (MDD).
METHODS: Using data from the National Comorbidity Survey-
Replication (NCS-R; n = 5692), respondents were categorized
into clinical severity categories (not clinically depressed, mild,
moderate, severe) using standard scales (CIDI/QIDS-SR). Out-
comes were measured over 12 months and included the preva-
lence of medical services and antidepressant use, the average
number of visits and days on antidepressants, the prevalence of
treatment adequacy, and medical and drug costs. Costs were
estimated by weighting utilization measures by unit costs
obtained for similar services used by depressed patients in a U.S.
privately insured claims database for the corresponding time
period (2000–2001). Outcomes were compared across depres-
sion severity groups using chi-square tests and regression models
that generated F statistics adjusted for demographics. RESULTS:
Among the 658 depressed respondents, 14.2% were mildly,
38.1% moderately and 47.7% severely depressed. Respondents
in the 3 groups shared similar demographic characteristics. There
was a signiﬁcant association between severity and the prevalence
of mental health services usage (20.8%, 27.9%, and 39.5%
respectively, p < 0.01) and the average number of mental health
practitioner visits. The use of antidepressants also increased with
depression severity (19.8%, 29.8%, and 40.2% respectively, p <
0.05). Similarly, the adequacy of mental health services increased
with depression severity (8.9%, 12.1%, and 21.3% respectively,
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p < 0.05). The average 12-month costs per MDD patient were
substantially higher for severe vs. mild (mental health services:
$718 vs. $416; general medical services: $133 vs. $57; anti-
depressant usage $275 vs. $89). CONCLUSIONS: There was a
signiﬁcant association between depression severity and treatment
usage and costs, as well as between treatment adequacy and
severity.
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OBJECTIVES: To compare the direct health care costs, during
and after pregnancy, between women who continue their antide-
pressant therapy during the whole gestational period and those
who discontinue their treatment during the ﬁrst trimester.
METHODS: Data from a ‘Medications and Pregnancy’ registry
were used. Eligible women were 1) aged 15—45, 2) insured by
the Quebec drug plan for 12 months prior to, during preg-
nancy, and 3 months after pregnancy, 3) had 1 diagnoses of
psychiatric disorders before pregnancy, 4) used antidepressants
for 30 days in the year before pregnancy, and 5) had delivered.
Women who continued their antidepressant therapy throughout
pregnancy (Group 1) were compared to those who discontinued
during the ﬁrst trimester (Group 2). Health care costs, expressed
as mean total costs and cost ratios were determined during and
after pregnancy. RESULTS: In total, 2822 women met inclusion
criteria. Of these, 501 (17.8%) were in Group 1, and 676
(23.4%) in Group 2. The median number of days of antidepres-
sant use before pregnancy was higher in Group 1 (260 days vs.
144 days, p < .01); the proportion of women visiting a psychia-
trist was also higher in Group 1 (33.7% vs. 26.8%, p < .01). The
mean total cost during pregnancy in Groups 1 and 2 were
$2981.5 vs. $1842.9 (p < .01), and after pregnancy $1761.2 vs.
$1024.9 (p < .01). When prescription costs were excluded, these
differences in costs were no longer signiﬁcant. CONCLUSIONS:
Women who use antidepressants during pregnancy are likely to
have disorders of greater severity compared to those who discon-
tinue during the ﬁrst trimester. They incur signiﬁcantly greater
health care costs. However, this increased cost is attributable to
higher prescription costs.
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OBJECTIVES: British guidelines recommend escitalopram and
venlafaxine as second-line treatments in major depressive disor-
der (MDD). Clinical trials demonstrated similar efﬁcacy and
better tolerability of escitalopram vs. venlafaxine. To assess how
these results translate into real-life, this study compared second-
line treatment strategies with escitalopram or venlafaxine after
failure of ﬁrst-line generic SSRI, based on drug utilisation and
economic outcomes in patients with MDD in the UK.
METHODS: This cohort study using the General Practitioners
Research Database (GPRD) included adults with a diagnosis of
MDD, who had switched from a ﬁrst-line generic SSRI to esci-
talopram or venlafaxine between January 1, 2003 and June 30,
2005. A 6-month drug utilisation outcomes were dose-
adjustments, mean treatment duration (TD), and successful
treatment stop (no subsequent need for treatment) after switch.
6-month economic outcomes were health care resource use and
total health care costs, calculated by adding up unit costs
applied to resources. Appropriate multivariate models were
built, using propensity scoring to control on baseline character-
istics. RESULTS: A total of 535 patients were switched to esci-
talopram, 1284 to venlafaxine. In the escitalopram cohort
compared with the venlafaxine cohort, there were fewer males
(32% vs. 38%, p = 0.02) and patients had a shorter median
time to switch (50 vs. 59 days, p = 0.005). Fewer drug adjust-
ments were needed with escitalopram (27% vs. 44%, p <
0.001); consequently, a shorter second-line treatment duration
(106 vs. 123 days, p = 0.003), numerically more successful stops
(37% vs. 32%, p = 0.25), and fewer GP visits (12.3 vs 13.4
visits/patient, p = 0.06) were observed in escitalopram-treated
patients. 6-month total health care costs were signiﬁcantly
lower with escitalopram (£629 vs £749, p = 0.028), and were
similar in both cohorts without treatment costs (£567 vs. £589,
p = 0.73). CONCLUSIONS: After failure of a ﬁrst generic SSRI,
second-line treatment with escitalopram was associated with
easier management, shorter second-line treatment duration and
earlier success, with no increase in health care cost, compared
with venlafaxine.
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OBJECTIVES: In the UK, guidelines recommend generic selec-
tive serotonin reuptake inhibitors (SSRIs) as ﬁrst-line treatment,
and more expensive drugs such as escitalopram or venlafaxine
as second-line treatment for major depressive disorder (MDD).
However, clinical trials have shown that escitalopram is more
efﬁcacious than SSRIs and at least as efﬁcacious as venlafaxine
with better tolerability in severe MDD. The objective of this
study was to compare ﬁrst-line treatment with generic SSRIs,
escitalopram or venlafaxine based on 12-month health care uti-
lization and associated direct costs in patients with severe MDD
in the UK. METHODS: This cohort study using the General
Practitioners Research Database (GPRD) included adults with a
diagnosis of MDD classiﬁed as severe by published algorithm,
and a new prescription of generic SSRI, escitalopram or ven-
lafaxine between 2003 and 2005. Twelve-month resource use
was assessed; annual total health care cost was calculated by
adding-up unit costs for all health care resources and compared
between treatments using a generalized linear model; propensity
scoring was used to control for confounders and baseline costs.
RESULTS: A total of 1947 patients started with a generic SSRI,
323 with escitalopram and 215 with venlafaxine. No difference
in baseline characteristics was seen between groups. After treat-
ment start, hospitalizations were less frequent in escitalopram-
treated patients vs. SSRIs (0.1 vs. 0.2 hospitalization per
patient, p = 0.05) or venlafaxine (0.1 vs 0.3, p < 0.01). Total
health care cost for escitalopram was numerically lower than
for generic SSRIs (£916 vs £974, p = NS) and signiﬁcantly lower
than for venlafaxine (£916 vs £1367, p < 0.001), also when
excluding drug costs (escitalopram vs. SSRIs: £831 vs. £957, p
= 0.10; vs. venlafaxine: £831 vs. £1156, p = 0.01). CONCLU-
SIONS: In severe MDD, costs associated with ﬁrst-line escitalo-
pram were similar to generic SSRIs, but lower than with
venlafaxine, independently of drug costs. The main driver was
the lower frequency of hospitalization for escitalopram-treated
patients.
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